ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Femasys Inc. (FEMY) stock surged +14.81%, trading at $1.24 on NASDAQ, up from the previous close of $1.08. The stock opened at $1.11, fluctuating between $1.09 and $1.24 in the recent session.
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Employees | 69 |
Beta | -2.55 |
Sales or Revenue | $1.07M |
5Y Sales Change% | -0.118% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Medical - Instruments & Supplies |